Monoclonal antibody to the HLA class I α3 domain inhibits T cell activation and prolongs cardiac allograft survival in HLA- transgenic mice

Jacky Woo, Marie Christine Cornejo, Lan Gao, Joel D Taurog, Robert E Hammer, Roland Buelow

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.

Original languageEnglish (US)
Pages (from-to)112-121
Number of pages10
JournalTransplant Immunology
Volume5
Issue number2
DOIs
StatePublished - Jun 1997

Fingerprint

Transgenic Mice
Allografts
Monoclonal Antibodies
T-Lymphocytes
Antibodies
Graft Survival
Lymphocytes
Ionomycin
Immunomodulation
Immunoglobulin Isotypes
Graft Rejection
Thymocytes
Inbred C57BL Mouse
Bone Marrow Cells
Interleukin-2
Therapeutics
Spleen
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Transplants

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Transplantation

Cite this

Monoclonal antibody to the HLA class I α3 domain inhibits T cell activation and prolongs cardiac allograft survival in HLA- transgenic mice. / Woo, Jacky; Cornejo, Marie Christine; Gao, Lan; Taurog, Joel D; Hammer, Robert E; Buelow, Roland.

In: Transplant Immunology, Vol. 5, No. 2, 06.1997, p. 112-121.

Research output: Contribution to journalArticle

@article{81813c93c44f4e7d86bd91c4cc56b4d9,
title = "Monoclonal antibody to the HLA class I α3 domain inhibits T cell activation and prolongs cardiac allograft survival in HLA- transgenic mice",
abstract = "Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.",
author = "Jacky Woo and Cornejo, {Marie Christine} and Lan Gao and Taurog, {Joel D} and Hammer, {Robert E} and Roland Buelow",
year = "1997",
month = "6",
doi = "10.1016/S0966-3274(97)80051-2",
language = "English (US)",
volume = "5",
pages = "112--121",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Monoclonal antibody to the HLA class I α3 domain inhibits T cell activation and prolongs cardiac allograft survival in HLA- transgenic mice

AU - Woo, Jacky

AU - Cornejo, Marie Christine

AU - Gao, Lan

AU - Taurog, Joel D

AU - Hammer, Robert E

AU - Buelow, Roland

PY - 1997/6

Y1 - 1997/6

N2 - Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.

AB - Antibodies recognizing MHC class I molecules expressed on the surface of T cells have been shown to inhibit T cell responses in vitro. These findings suggested that therapy with such an antibody may prevent rejection and promote graft acceptance. We therefore tested the effect of an anti-HLA class I α3 domain antibody (TP25.99) in vivo using transgenic C57BL/6 mice expressing HLA- B2705. Flow cytometric analysis confirmed the binding of TP25.99 to normal human peripheral blood lymphocytes and to mouse spleen cells, bone marrow cells and thymocytes isolated from hemizygous (+/-) transgenic littermates but not from homozygous (-/-) littermates. TP25.99 inhibited OKT-3-induced, but not PMA+ionomycin-induced, proliferation of human peripheral blood lymphocyte as well as anti-CD3 or Con A-induced proliferation of HLA+ mouse T cells. Both intact monoclonal antibody TP25.99 and TP25.99 Fab inhibited T cell proliferation. Reduced proliferation was associated with suppressed production of interleukin-2 as measured by ELISA. The efficacy of TP25.99 Fab in vivo was evaluated in a heart allograft model. Antibody therapy of (H-2b, B2705+) transgenic recipients of allogeneic Balb/c (H-2(d)) heart grafts prolonged graft survival significantly (MST = 19.8 ± 6.4, p = 0.003) compared to treated (H-2b, B2705-) (MST = 9.17 ± 2.2) or untreated (H-2b, B2705+) (MST = 10.0 ± 2.8) transgenic recipients. This demonstrates that immunomodulation through anti-HLA class I antibody therapy can lead to prolongation of graft survival.

UR - http://www.scopus.com/inward/record.url?scp=0030851957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851957&partnerID=8YFLogxK

U2 - 10.1016/S0966-3274(97)80051-2

DO - 10.1016/S0966-3274(97)80051-2

M3 - Article

C2 - 9269033

AN - SCOPUS:0030851957

VL - 5

SP - 112

EP - 121

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

IS - 2

ER -